h 1152 profile

(S)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane : A member of the class of isoquinolines that is the sulfonamide formed by the formal condensation of the sulfo group of 4-methylisoquinoline-5-sulfonic acid with the 1-amino group of (S)-2-methyl-1,4-diazepane. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ID Source	ID
PubMed CID	448043
CHEMBL ID	406821
CHEBI ID	88220
SCHEMBL ID	124161
MeSH ID	M0430006

Synonym
(s)-2-methyl-1-[(4-methyl-5-isoquinoline)sulfonyl]-homopiperazine
H52 ,
2GNH
1Q8U
2GNL
h-1152p
h-1152
bdbm14028
4-methyl-5-{[(2s)-2-methyl-1,4-diazepane-1-]sulfonyl}isoquinoline
chebi:88220 ,
CHEMBL406821
4-methyl-5-[[(2s)-2-methyl-1,4-diazepan-1-yl]sulfonyl]isoquinoline
DB07876
dimethylfasudil
h 1152
CS-1536
HY-15720
SCHEMBL124161
(s)-4-methyl-5-((2-methyl-1,4-diazepan-1-yl)sulfonyl)isoquinoline
4-methyl-5-[(2s)-2-methyl-1,4-diazepane-1-sulfonyl]isoquinoline
(s)-2-methyl-1-(4-methylisoquinoline-5-sulfonyl)-1,4-diazepane
(s)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]homopiperazine
dimethyl fasudil
DTXSID20735620
AKOS027263830
(s)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl]-homopiperazine
4-methyl-5-{[(2s)-2-methyl-1,4-diazepan-1-yl]sulfonyl}isoquinoline
BCP16935
(s)-h-1152 (hydrochloride)
(s)-(+)-2-methyl-1-[(4-methyl-5-isoquinolinyl)sulfonyl] -hexahydro-1h-1,4-diazepine dihydrochloride
Q27097084
NCGC00378616-03
nsc-780205
nsc780205

Excerpt	Reference	Relevance
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."	( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019)	0.51

Role	Description
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor	An EC 2.7.11.* (protein-serine/threonine kinase) inhibitor that interferes with the action of non-specific serine/threonine protein kinase (EC 2.7.11.1), a kinase enzyme involved in phosphorylation of hydroxy group of serine or threonine.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Class	Description
isoquinolines	A class of organic heteropolycyclic compound consisting of isoquinoline and its substitution derivatives.
N-sulfonyldiazepane
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein	Taxonomy	Measurement	Average	Min (ref.)	Avg (ref.)	Max (ref.)	Bioassay(s)
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit	Bos taurus (cattle)	IC50 (µMol)	0.1035	0.0580	2.8974	6.0000	AID977608
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit	Bos taurus (cattle)	IC50 (µMol)	0.1035	0.0580	2.8974	6.0000	AID977608
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit	Bos taurus (cattle)	IC50 (µMol)	0.1035	0.0580	2.8974	6.0000	AID977608
Chain I, cAMP-dependent protein kinase inhibitor alpha	synthetic construct	IC50 (µMol)	0.1035	0.0580	2.8974	6.0000	AID977608
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit	Bos taurus (cattle)	IC50 (µMol)	0.1035	0.0580	2.8974	6.0000	AID977608
Chain A, cAMP-dependent protein kinase, alpha-catalytic subunit	Bos taurus (cattle)	IC50 (µMol)	0.1035	0.0580	2.8974	6.0000	AID977608
Chain I, cAMP-dependent protein kinase inhibitor alpha	synthetic construct	IC50 (µMol)	0.1035	0.0580	2.8974	6.0000	AID977608
Serine/threonine-protein kinase PLK4	Homo sapiens (human)	Ki	15.0300	0.0003	0.9559	9.3000	AID1798514
Rho-associated protein kinase 2	Homo sapiens (human)	IC50 (µMol)	0.0097	0.0002	0.5780	10.0000	AID1165785; AID1295304; AID456627
cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)	IC50 (µMol)	0.3254	0.0020	1.2409	9.0000	AID1797134
cAMP-dependent protein kinase catalytic subunit alpha	Mus musculus (house mouse)	Ki	0.1730	0.0060	0.5480	2.2000	AID1797144
cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)	Ki	0.3400	0.0047	0.9332	3.0000	AID435508
cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)	Ki	0.3400	0.0047	1.2009	3.0000	AID435508
cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)	Ki	0.3400	0.0047	1.2009	3.0000	AID435508
Serine/threonine-protein kinase PLK1	Homo sapiens (human)	Ki	15.0300	0.0002	1.0608	9.3000	AID1798514
Rho-associated protein kinase 1	Homo sapiens (human)	IC50 (µMol)	0.0050	0.0004	0.8549	10.0000	AID1165784
Rho-associated protein kinase 1	Homo sapiens (human)	Ki	0.0895	0.0020	0.3067	2.2000	AID1797144; AID435637; AID456626
Myosin light chain kinase, smooth muscle	Homo sapiens (human)	Ki	10.1000	0.0200	2.8367	7.4000	AID325587
Rho-associated protein kinase 2	Bos taurus (cattle)	IC50 (µMol)	0.3254	0.0012	1.3884	9.0000	AID1797134
Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)	IC50 (µMol)	0.2440	0.0004	0.3943	8.3000	AID756067
Serine/threonine-protein kinase PLK3	Homo sapiens (human)	Ki	15.0300	0.0010	1.2726	9.3000	AID1798514
Serine/threonine-protein kinase PLK2	Homo sapiens (human)	Ki	15.0300	0.0010	1.2726	9.3000	AID1798514
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Process	via Protein(s)	Taxonomy
positive regulation of centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
positive regulation of centriole replication	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cilium assembly	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
trophoblast giant cell differentiation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
de novo centriole assembly involved in multi-ciliated epithelial cell differentiation	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
epithelial to mesenchymal transition	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of protein phosphorylation	Rho-associated protein kinase 2	Homo sapiens (human)
response to ischemia	Rho-associated protein kinase 2	Homo sapiens (human)
aortic valve morphogenesis	Rho-associated protein kinase 2	Homo sapiens (human)
protein phosphorylation	Rho-associated protein kinase 2	Homo sapiens (human)
smooth muscle contraction	Rho-associated protein kinase 2	Homo sapiens (human)
canonical NF-kappaB signal transduction	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of endothelial cell migration	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of gene expression	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of gene expression	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of centrosome duplication	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of angiogenesis	Rho-associated protein kinase 2	Homo sapiens (human)
actin cytoskeleton organization	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of cell adhesion	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of cell migration	Rho-associated protein kinase 2	Homo sapiens (human)
cortical actin cytoskeleton organization	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of nervous system process	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of connective tissue growth factor production	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of actin cytoskeleton organization	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activity	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of circadian rhythm	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of MAPK cascade	Rho-associated protein kinase 2	Homo sapiens (human)
modulation by host of viral process	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of nitric oxide biosynthetic process	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of keratinocyte differentiation	Rho-associated protein kinase 2	Homo sapiens (human)
rhythmic process	Rho-associated protein kinase 2	Homo sapiens (human)
centrosome duplication	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of stress fiber assembly	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of stress fiber assembly	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of focal adhesion assembly	Rho-associated protein kinase 2	Homo sapiens (human)
mRNA destabilization	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of biomineral tissue development	Rho-associated protein kinase 2	Homo sapiens (human)
cellular response to testosterone stimulus	Rho-associated protein kinase 2	Homo sapiens (human)
response to transforming growth factor beta	Rho-associated protein kinase 2	Homo sapiens (human)
protein localization to plasma membrane	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of fibroblast growth factor production	Rho-associated protein kinase 2	Homo sapiens (human)
blood vessel diameter maintenance	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of angiotensin-activated signaling pathway	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of protein localization to lysosome	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of cellular response to hypoxia	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of amyloid-beta formation	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of protein localization to early endosome	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of amyloid precursor protein catabolic process	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of establishment of endothelial barrier	Rho-associated protein kinase 2	Homo sapiens (human)
negative regulation of bicellular tight junction assembly	Rho-associated protein kinase 2	Homo sapiens (human)
cellular response to acetylcholine	Rho-associated protein kinase 2	Homo sapiens (human)
positive regulation of connective tissue replacement	Rho-associated protein kinase 2	Homo sapiens (human)
response to angiotensin	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of establishment of cell polarity	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of cell motility	Rho-associated protein kinase 2	Homo sapiens (human)
actomyosin structure organization	Rho-associated protein kinase 2	Homo sapiens (human)
peptidyl-threonine phosphorylation	Rho-associated protein kinase 2	Homo sapiens (human)
mitotic cytokinesis	Rho-associated protein kinase 2	Homo sapiens (human)
embryonic morphogenesis	Rho-associated protein kinase 2	Homo sapiens (human)
regulation of cell junction assembly	Rho-associated protein kinase 2	Homo sapiens (human)
Rho protein signal transduction	Rho-associated protein kinase 2	Homo sapiens (human)
mesoderm formation	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein phosphorylation	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
peptidyl-serine phosphorylation	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
cellular response to heat	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
negative regulation of TORC1 signaling	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
mesoderm formation	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
neural tube closure	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of heart rate	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
renal water homeostasis	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
mRNA processing	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein phosphorylation	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein export from nucleus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
adenylate cyclase-activating G protein-coupled receptor signaling pathway	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of cardiac muscle contraction by regulation of the release of sequestered calcium ion	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of macroautophagy	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
peptidyl-serine phosphorylation	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cytokine-mediated signaling pathway	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
positive regulation of insulin secretion	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
negative regulation of interleukin-2 production	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
high-density lipoprotein particle assembly	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cellular response to heat	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
mitochondrial protein catabolic process	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of osteoblast differentiation	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
positive regulation of gluconeogenesis	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
negative regulation of smoothened signaling pathway	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
positive regulation of protein export from nucleus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
sperm capacitation	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
positive regulation of calcium-mediated signaling	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of cell cycle	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of cardiac muscle contraction	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of proteasomal protein catabolic process	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cellular response to cold	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of protein processing	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cellular response to glucose stimulus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cellular response to parathyroid hormone stimulus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cellular response to glucagon stimulus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cellular response to epinephrine stimulus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cell communication by electrical coupling involved in cardiac conduction	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
postsynaptic modulation of chemical synaptic transmission	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of cardiac conduction	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
negative regulation of TORC1 signaling	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
negative regulation of glycolytic process through fructose-6-phosphate	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein localization to lipid droplet	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
regulation of bicellular tight junction assembly	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein kinase A signaling	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
renal water homeostasis	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
spermatogenesis	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
male gonad development	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
high-density lipoprotein particle assembly	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
protein kinase A signaling	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
neural tube closure	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
renal water homeostasis	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
protein phosphorylation	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
signal transduction	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathway	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
high-density lipoprotein particle assembly	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
negative regulation of smoothened signaling pathway	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
regulation of protein processing	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
negative regulation of TORC1 signaling	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
protein kinase A signaling	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
establishment of protein localization	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic sister chromatid segregation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
establishment of mitotic spindle orientation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic cytokinesis	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
microtubule bundle formation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
double-strand break repair	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic spindle organization	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
sister chromatid cohesion	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic chromosome condensation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic nuclear membrane disassembly	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
metaphase/anaphase transition of mitotic cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic spindle assembly checkpoint signaling	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic G2 DNA damage checkpoint signaling	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centrosome cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of mitotic cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of peptidyl-threonine phosphorylation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
female meiosis chromosome segregation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein ubiquitination	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of mitotic metaphase/anaphase transition	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein destabilization	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of cytokinesis	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
negative regulation of apoptotic process	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of protein binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
homologous chromosome segregation	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
negative regulation of cyclin-dependent protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of proteolysis	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
Golgi inheritance	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
nuclear membrane disassembly	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of ubiquitin-protein transferase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of cell cycle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
synaptonemal complex disassembly	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein localization to chromatin	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein localization to nuclear envelope	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
double-strand break repair via alternative nonhomologous end joining	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of protein localization to nucleus	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of mitotic spindle assembly	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of mitotic cell cycle phase transition	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
positive regulation of ubiquitin protein ligase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of protein localization to cell cortex	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
regulation of anaphase-promoting complex-dependent catabolic process	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
negative regulation of double-strand break repair via homologous recombination	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
epithelial to mesenchymal transition	Rho-associated protein kinase 1	Homo sapiens (human)
aortic valve morphogenesis	Rho-associated protein kinase 1	Homo sapiens (human)
apical constriction	Rho-associated protein kinase 1	Homo sapiens (human)
protein phosphorylation	Rho-associated protein kinase 1	Homo sapiens (human)
smooth muscle contraction	Rho-associated protein kinase 1	Homo sapiens (human)
leukocyte cell-cell adhesion	Rho-associated protein kinase 1	Homo sapiens (human)
signal transduction	Rho-associated protein kinase 1	Homo sapiens (human)
canonical NF-kappaB signal transduction	Rho-associated protein kinase 1	Homo sapiens (human)
Rho protein signal transduction	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of autophagy	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of cardiac muscle hypertrophy	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of gene expression	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of phosphatase activity	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of angiogenesis	Rho-associated protein kinase 1	Homo sapiens (human)
peptidyl-serine phosphorylation	Rho-associated protein kinase 1	Homo sapiens (human)
membrane to membrane docking	Rho-associated protein kinase 1	Homo sapiens (human)
actin cytoskeleton organization	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of cell adhesion	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of cell migration	Rho-associated protein kinase 1	Homo sapiens (human)
cortical actin cytoskeleton organization	Rho-associated protein kinase 1	Homo sapiens (human)
neuron projection development	Rho-associated protein kinase 1	Homo sapiens (human)
bleb assembly	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of protein binding	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of actin cytoskeleton organization	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of dephosphorylation	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of myosin-light-chain-phosphatase activity	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of phosphorylation	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of MAPK cascade	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of keratinocyte differentiation	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of neuron differentiation	Rho-associated protein kinase 1	Homo sapiens (human)
leukocyte migration	Rho-associated protein kinase 1	Homo sapiens (human)
leukocyte tethering or rolling	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of membrane protein ectodomain proteolysis	Rho-associated protein kinase 1	Homo sapiens (human)
myoblast migration	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of stress fiber assembly	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of focal adhesion assembly	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of focal adhesion assembly	Rho-associated protein kinase 1	Homo sapiens (human)
mRNA destabilization	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of biomineral tissue development	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of microtubule cytoskeleton organization	Rho-associated protein kinase 1	Homo sapiens (human)
response to transforming growth factor beta	Rho-associated protein kinase 1	Homo sapiens (human)
protein localization to plasma membrane	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of synapse maturation	Rho-associated protein kinase 1	Homo sapiens (human)
podocyte cell migration	Rho-associated protein kinase 1	Homo sapiens (human)
motor neuron apoptotic process	Rho-associated protein kinase 1	Homo sapiens (human)
blood vessel diameter maintenance	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of angiotensin-activated signaling pathway	Rho-associated protein kinase 1	Homo sapiens (human)
neuron projection arborization	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of amyloid-beta clearance	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of synaptic vesicle endocytosis	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of amyloid-beta formation	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of amyloid precursor protein catabolic process	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of establishment of endothelial barrier	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of bicellular tight junction assembly	Rho-associated protein kinase 1	Homo sapiens (human)
positive regulation of connective tissue replacement	Rho-associated protein kinase 1	Homo sapiens (human)
response to angiotensin	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of establishment of cell polarity	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of cell motility	Rho-associated protein kinase 1	Homo sapiens (human)
negative regulation of motor neuron apoptotic process	Rho-associated protein kinase 1	Homo sapiens (human)
regulation of cell junction assembly	Rho-associated protein kinase 1	Homo sapiens (human)
mitotic cytokinesis	Rho-associated protein kinase 1	Homo sapiens (human)
embryonic morphogenesis	Rho-associated protein kinase 1	Homo sapiens (human)
peptidyl-threonine phosphorylation	Rho-associated protein kinase 1	Homo sapiens (human)
actomyosin structure organization	Rho-associated protein kinase 1	Homo sapiens (human)
protein phosphorylation	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
smooth muscle contraction	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
tonic smooth muscle contraction	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
positive regulation of cell migration	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
bleb assembly	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
positive regulation of calcium ion transport	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
aorta smooth muscle tissue morphogenesis	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cellular hypotonic response	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
positive regulation of wound healing	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
smooth muscle contraction	Rho-associated protein kinase 2	Bos taurus (cattle)
positive regulation of centrosome duplication	Rho-associated protein kinase 2	Bos taurus (cattle)
actin cytoskeleton organization	Rho-associated protein kinase 2	Bos taurus (cattle)
regulation of actin cytoskeleton organization	Rho-associated protein kinase 2	Bos taurus (cattle)
regulation of circadian rhythm	Rho-associated protein kinase 2	Bos taurus (cattle)
rhythmic process	Rho-associated protein kinase 2	Bos taurus (cattle)
negative regulation of GTPase activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
MAPK cascade	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
negative regulation of protein phosphorylation	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of protein phosphorylation	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
protein phosphorylation	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
protein import into nucleus	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
endocytosis	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
autophagy	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
response to oxidative stress	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
mitochondrion organization	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
endoplasmic reticulum organization	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
Golgi organization	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
lysosome organization	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
JNK cascade	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
Rho protein signal transduction	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
spermatogenesis	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
neuromuscular junction development	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
protein localization	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
determination of adult lifespan	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
cellular response to starvation	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of autophagy	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of autophagy	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of protein kinase A signaling	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
negative regulation of protein processing	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
negative regulation of neuron projection development	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of neuron maturation	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
negative regulation of macroautophagy	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
phosphorylation	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
peptidyl-serine phosphorylation	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
peptidyl-threonine phosphorylation	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
calcium-mediated signaling	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
striatum development	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
olfactory bulb development	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
tangential migration from the subventricular zone to the olfactory bulb	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of protein ubiquitination	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of protein stability	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
negative regulation of protein binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of protein binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of tumor necrosis factor production	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
cellular response to oxidative stress	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
cellular response to reactive oxygen species	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
intracellular signal transduction	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of kidney size	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
exploration behavior	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
locomotory exploration behavior	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of lysosomal lumen pH	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of locomotion	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of membrane potential	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of programmed cell death	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of MAP kinase activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of protein kinase activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
GTP metabolic process	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
protein autophosphorylation	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
intracellular distribution of mitochondria	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
neuron projection morphogenesis	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
mitochondrion localization	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of nitric-oxide synthase biosynthetic process	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of mitochondrial depolarization	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of synaptic transmission, glutamatergic	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
canonical Wnt signaling pathway	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
excitatory postsynaptic potential	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of dopamine receptor signaling pathway	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of dopamine receptor signaling pathway	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of ER to Golgi vesicle-mediated transport	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of canonical Wnt signaling pathway	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of dendritic spine morphogenesis	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
protein localization to mitochondrion	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
protein localization to endoplasmic reticulum exit site	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
cellular response to manganese ion	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of mitochondrial fission	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of canonical Wnt signaling pathway	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
negative regulation of excitatory postsynaptic potential	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
neuron projection arborization	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of synaptic vesicle endocytosis	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
negative regulation of endoplasmic reticulum stress-induced intrinsic apoptotic signaling pathway	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of protein autoubiquitination	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of neuroblast proliferation	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of synaptic vesicle transport	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
negative regulation of late endosome to lysosome transport	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
negative regulation of autophagosome assembly	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
negative regulation of thioredoxin peroxidase activity by peptidyl-threonine phosphorylation	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
negative regulation of protein targeting to mitochondrion	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
negative regulation of protein processing involved in protein targeting to mitochondrion	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
cellular response to dopamine	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
positive regulation of microglial cell activation	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
Wnt signalosome assembly	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of retrograde transport, endosome to Golgi	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of CAMKK-AMPK signaling cascade	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of branching morphogenesis of a nerve	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of synaptic vesicle exocytosis	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
regulation of reactive oxygen species metabolic process	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
signal transduction	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
G2/M transition of mitotic cell cycle	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
negative regulation of transcription by RNA polymerase II	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
response to reactive oxygen species	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
apoptotic process	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
response to osmotic stress	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
DNA damage response	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
endomitotic cell cycle	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
response to radiation	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
cytoplasmic microtubule organization	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
regulation of cytokinesis	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
negative regulation of apoptotic process	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
mitotic G1/S transition checkpoint signaling	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
regulation of cell division	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
negative regulation of phosphatidylinositol 3-kinase/protein kinase B signal transduction	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
Golgi disassembly	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
positive regulation of intracellular protein transport	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
regulation of signal transduction by p53 class mediator	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
positive regulation of chaperone-mediated autophagy	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic process involved in cellular response to hypoxia	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
mitotic spindle organization	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
G1/S transition of mitotic cell cycle	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
negative regulation of inflammatory response to antigenic stimulus	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
protein phosphorylation	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrest	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
mitotic spindle organization	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
Ras protein signal transduction	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
memory	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
positive regulation of autophagy	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
negative regulation of angiogenesis	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
peptidyl-serine phosphorylation	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
Rap protein signal transduction	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
negative regulation of apoptotic process	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
positive regulation of canonical NF-kappaB signal transduction	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
positive regulation of protein catabolic process	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
regulation of centriole replication	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
regulation of synaptic plasticity	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
long-term synaptic potentiation	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
long-term synaptic depression	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
negative regulation of apoptotic process in bone marrow cell	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
positive regulation of cell migration involved in sprouting angiogenesis	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
negative regulation of cellular senescence	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
protease binding	Rho-associated protein kinase 2	Homo sapiens (human)
RNA binding	Rho-associated protein kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
structural molecule activity	Rho-associated protein kinase 2	Homo sapiens (human)
protein binding	Rho-associated protein kinase 2	Homo sapiens (human)
ATP binding	Rho-associated protein kinase 2	Homo sapiens (human)
small GTPase binding	Rho-associated protein kinase 2	Homo sapiens (human)
metal ion binding	Rho-associated protein kinase 2	Homo sapiens (human)
tau protein binding	Rho-associated protein kinase 2	Homo sapiens (human)
tau-protein kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
endopeptidase activator activity	Rho-associated protein kinase 2	Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
protein serine kinase activity	Rho-associated protein kinase 2	Homo sapiens (human)
protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein serine/threonine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
AMP-activated protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
cAMP-dependent protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein binding	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
ATP binding	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein domain specific binding	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein serine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
protein serine/threonine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Mus musculus (house mouse)
cAMP-dependent protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Mus musculus (house mouse)
magnesium ion binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein serine/threonine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
AMP-activated protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cAMP-dependent protein kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein serine/threonine/tyrosine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
ATP binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein kinase binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein domain specific binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
manganese ion binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
ubiquitin protein ligase binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein kinase A regulatory subunit binding	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
channel activator activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein serine kinase activity	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
protein serine/threonine kinase activity	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
AMP-activated protein kinase activity	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
cAMP-dependent protein kinase activity	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
protein binding	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
ATP binding	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
protein serine kinase activity	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
protein kinase A regulatory subunit binding	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
magnesium ion binding	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
protein serine/threonine kinase activity	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
AMP-activated protein kinase activity	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
cAMP-dependent protein kinase activity	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
protein binding	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
ATP binding	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
ubiquitin protein ligase binding	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
protein serine kinase activity	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
magnesium ion binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein kinase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
microtubule binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
anaphase-promoting complex binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein kinase binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
identical protein binding	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
protein kinase activity	Rho-associated protein kinase 1	Homo sapiens (human)
protein serine/threonine kinase activity	Rho-associated protein kinase 1	Homo sapiens (human)
protein binding	Rho-associated protein kinase 1	Homo sapiens (human)
ATP binding	Rho-associated protein kinase 1	Homo sapiens (human)
small GTPase binding	Rho-associated protein kinase 1	Homo sapiens (human)
metal ion binding	Rho-associated protein kinase 1	Homo sapiens (human)
tau protein binding	Rho-associated protein kinase 1	Homo sapiens (human)
tau-protein kinase activity	Rho-associated protein kinase 1	Homo sapiens (human)
Rho-dependent protein serine/threonine kinase activity	Rho-associated protein kinase 1	Homo sapiens (human)
protein serine kinase activity	Rho-associated protein kinase 1	Homo sapiens (human)
actin binding	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
myosin light chain kinase activity	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
protein binding	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
calmodulin binding	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
ATP binding	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
metal ion binding	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
protein serine/threonine kinase activity	Rho-associated protein kinase 2	Bos taurus (cattle)
protein kinase activity	Rho-associated protein kinase 2	Bos taurus (cattle)
ATP binding	Rho-associated protein kinase 2	Bos taurus (cattle)
small GTPase binding	Rho-associated protein kinase 2	Bos taurus (cattle)
metal ion binding	Rho-associated protein kinase 2	Bos taurus (cattle)
protein serine kinase activity	Rho-associated protein kinase 2	Bos taurus (cattle)
SNARE binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
magnesium ion binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
actin binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
GTPase activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
protein kinase activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
protein serine/threonine kinase activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
JUN kinase kinase kinase activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
MAP kinase kinase kinase activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
GTPase activator activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
protein binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
ATP binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
GTP binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
microtubule binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
tubulin binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
kinase activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
syntaxin-1 binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
signaling receptor complex adaptor activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
clathrin binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
small GTPase binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
GTP-dependent protein kinase activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
peroxidase inhibitor activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
co-receptor binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
identical protein binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
protein homodimerization activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
transmembrane transporter binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
protein kinase A binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
protein serine kinase activity	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
beta-catenin destruction complex binding	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
p53 binding	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
protein serine/threonine kinase activity	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
protein binding	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
ATP binding	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
ATP-dependent protein binding	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
protein serine kinase activity	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Process	via Protein(s)	Taxonomy
XY body	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
nucleolus	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
centriole	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
cleavage furrow	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
deuterosome	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
procentriole	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
procentriole replication complex	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK4	Homo sapiens (human)
nucleus	Rho-associated protein kinase 2	Homo sapiens (human)
centrosome	Rho-associated protein kinase 2	Homo sapiens (human)
cytosol	Rho-associated protein kinase 2	Homo sapiens (human)
plasma membrane	Rho-associated protein kinase 2	Homo sapiens (human)
cytoplasmic ribonucleoprotein granule	Rho-associated protein kinase 2	Homo sapiens (human)
centrosome	Rho-associated protein kinase 2	Homo sapiens (human)
cytoskeleton	Rho-associated protein kinase 2	Homo sapiens (human)
cytoplasm	Rho-associated protein kinase 2	Homo sapiens (human)
acrosomal vesicle	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
nucleus	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
cytoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
mitochondrion	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
plasma membrane	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
neuromuscular junction	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
sperm flagellum	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
perinuclear region of cytoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
cAMP-dependent protein kinase complex	cAMP-dependent protein kinase catalytic subunit alpha	Bos taurus (cattle)
nucleoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Mus musculus (house mouse)
cytosol	cAMP-dependent protein kinase catalytic subunit alpha	Mus musculus (house mouse)
axoneme	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cytoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
acrosomal vesicle	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
nucleus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
nucleoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cytoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
mitochondrial matrix	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
centrosome	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
plasma membrane	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
nuclear speck	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
neuromuscular junction	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
sperm flagellum	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
dendritic spine	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
plasma membrane raft	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
perinuclear region of cytoplasm	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
extracellular exosome	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
ciliary base	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
glutamatergic synapse	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cAMP-dependent protein kinase complex	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
calcium channel complex	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
nucleus	cAMP-dependent protein kinase catalytic subunit alpha	Homo sapiens (human)
nucleoplasm	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
ciliary base	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
nucleus	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
cAMP-dependent protein kinase complex	cAMP-dependent protein kinase catalytic subunit gamma	Homo sapiens (human)
nucleoplasm	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
centrosome	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
plasma membrane	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
extracellular exosome	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
ciliary base	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
cAMP-dependent protein kinase complex	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
cytosol	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
nucleus	cAMP-dependent protein kinase catalytic subunit beta	Homo sapiens (human)
spindle microtubule	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
kinetochore	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
synaptonemal complex	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centriole	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
spindle	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
microtubule cytoskeleton	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
midbody	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centriolar satellite	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
spindle midzone	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
mitotic spindle pole	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
chromatin	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
outer kinetochore	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
kinetochore	Serine/threonine-protein kinase PLK1	Homo sapiens (human)
Golgi membrane	Rho-associated protein kinase 1	Homo sapiens (human)
ruffle	Rho-associated protein kinase 1	Homo sapiens (human)
extracellular region	Rho-associated protein kinase 1	Homo sapiens (human)
centriole	Rho-associated protein kinase 1	Homo sapiens (human)
cytosol	Rho-associated protein kinase 1	Homo sapiens (human)
cytoskeleton	Rho-associated protein kinase 1	Homo sapiens (human)
plasma membrane	Rho-associated protein kinase 1	Homo sapiens (human)
cytoplasmic stress granule	Rho-associated protein kinase 1	Homo sapiens (human)
lamellipodium	Rho-associated protein kinase 1	Homo sapiens (human)
bleb	Rho-associated protein kinase 1	Homo sapiens (human)
secretory granule lumen	Rho-associated protein kinase 1	Homo sapiens (human)
Schaffer collateral - CA1 synapse	Rho-associated protein kinase 1	Homo sapiens (human)
cytoskeleton	Rho-associated protein kinase 1	Homo sapiens (human)
cytoplasm	Rho-associated protein kinase 1	Homo sapiens (human)
cytoplasmic stress granule	Rho-associated protein kinase 1	Homo sapiens (human)
stress fiber	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cytoplasm	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cytosol	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
plasma membrane	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
actin cytoskeleton	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
lamellipodium	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cleavage furrow	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cleavage furrow	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
stress fiber	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
lamellipodium	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cytoplasm	Myosin light chain kinase, smooth muscle	Homo sapiens (human)
cytosol	Rho-associated protein kinase 2	Bos taurus (cattle)
nucleus	Rho-associated protein kinase 2	Bos taurus (cattle)
plasma membrane	Rho-associated protein kinase 2	Bos taurus (cattle)
Golgi membrane	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
extracellular space	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
cytoplasm	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
mitochondrion	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
mitochondrial outer membrane	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
mitochondrial inner membrane	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
mitochondrial matrix	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
lysosome	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
endosome	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
endoplasmic reticulum	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
endoplasmic reticulum membrane	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
Golgi apparatus	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
Golgi-associated vesicle	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
trans-Golgi network	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
cytosol	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
cytoskeleton	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
plasma membrane	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
microvillus	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
axon	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
dendrite	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
growth cone	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
synaptic vesicle membrane	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
cytoplasmic vesicle	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
mitochondrial membrane	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
cytoplasmic side of mitochondrial outer membrane	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
dendrite cytoplasm	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
neuron projection	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
neuronal cell body	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
terminal bouton	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
perikaryon	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
intracellular membrane-bounded organelle	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
amphisome	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
autolysosome	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
extracellular exosome	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
endoplasmic reticulum exit site	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
multivesicular body, internal vesicle	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
postsynapse	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
glutamatergic synapse	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
caveola neck	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
presynaptic cytosol	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
ribonucleoprotein complex	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
Wnt signalosome	Leucine-rich repeat serine/threonine-protein kinase 2	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
nucleoplasm	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
nucleolus	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
Golgi stack	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
dendrite	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
neuronal cell body	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
kinetochore	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PLK3	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
centriole	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
cytosol	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
dendrite	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
chromatin	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
spindle pole	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
centriole	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
centrosome	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
cytoplasm	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
kinetochore	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
nucleus	Serine/threonine-protein kinase PLK2	Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (152)

Assay ID	Title	Year	Journal	Article
AID435374	Percentage PLK1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435842	Percentage Aurora C activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435995	Percentage SRPK1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435350	Percentage ERK2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224795	Delta TM value showing the stabilisation of SLK produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224756	Delta TM value showing the stabilisation of CAMKK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435233	Percentage HIPK3 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435315	Percentage MARK3 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435756	Percentage Src activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435225	Percentage DYRK3 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435681	Percentage MAPKAPK2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435723	Percentage GSK3-beta activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435228	Percentage ERK1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224784	Delta TM value showing the stabilisation of PCTK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435613	Percentage MNK1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224804	Delta TM value showing the stabilisation of VRK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224773	Delta TM value showing the stabilisation of ASK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224796	Delta TM value showing the stabilisation of LOK produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID436086	Percentage HIPK2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224760	Delta TM value showing the stabilisation of CHEK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435378	Percentage S6K1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224781	Delta TM value showing the stabilisation of PAK4 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435962	Percentage CDK2-cyclinA activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435819	Percentage PKBbeta activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435373	Percentage PKCzeta activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224799	Delta TM value showing the stabilisation of NDR1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435317	Percentage PIM1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435865	Percentage MKK1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID436072	Percentage CK1delta activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224786	Delta TM value showing the stabilisation of PIM1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID456626	Inhibition of human ROCK1 by homogenous luciferase assay	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.
AID435704	Percentage Aurora B activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID756067	Inhibition of human N-terminal GST-tagged LRRK2 after 1 hr by TR-FRET assay	2013	Bioorganic & medicinal chemistry letters, Jul-01, Volume: 23, Issue:13	The development of CNS-active LRRK2 inhibitors using property-directed optimisation.
AID1224761	Delta TM value showing the stabilisation of CLK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224752	Delta TM value showing the stabilisation of CAMK2B produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID325586	Binding affinity at PKC	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224798	Delta TM value showing the stabilisation of DRAK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435727	Percentage JNK2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435867	Percentage NEK2a activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435881	Percentage ROCK2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435820	Percentage PKCalpha activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435854	Percentage IKK-beta activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224758	Delta TM value showing the stabilisation of CDK6 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224792	Delta TM value showing the stabilisation of RIOK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435706	Percentage BRSK2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224807	Delta TM value showing the stabilisation of YSK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID436083	Percentage ERK8 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435223	Percentage CSK activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224788	Delta TM value showing the stabilisation of PIM3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224791	Delta TM value showing the stabilisation of PRKACA produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435215	Percentage AMPK activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224775	Delta TM value showing the stabilisation of ERK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID456627	Inhibition of human ROCK2 by homogenous luciferase assay	2010	Journal of medicinal chemistry, Jan-28, Volume: 53, Issue:2	Hit to lead account of the discovery of bisbenzamide and related ureidobenzamide inhibitors of Rho kinase.
AID1224789	Delta TM value showing the stabilisation of PLK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435260	Percentage RSK2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435883	Percentage SGK1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435338	Percentage CaMK1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224776	Delta TM value showing the stabilisation of ERK3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224803	Delta TM value showing the stabilisation of PBK produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435731	Percentage MNK2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224785	Delta TM value showing the stabilisation of PDK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435300	Percentage PAK6 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID325588	Inhibition of lysophosphatidic acid-induced MARCKS phosphorylation in human NT2 cells	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224806	Delta TM value showing the stabilisation of VRK3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224759	Delta TM value showing the stabilisation of CDKL1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224800	Delta TM value showing the stabilisation of MST4 (2) produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435508	Inhibitory constant against PKA	2006	The Journal of biological chemistry, Jan-06, Volume: 281, Issue:1	The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.
AID435418	Percentage PAK5 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435461	Percentage CK2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224757	Delta TM value showing the stabilisation of CDK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435539	Percentage PHK activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435734	Percentage NEK6 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435375	Percentage RSK1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435250	Percentage MSK1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224762	Delta TM value showing the stabilisation of CLK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435370	Percentage p38beta MAPK activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435363	Percentage MELK activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID325587	Binding affinity at MLCK	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224763	Delta TM value showing the stabilisation of CLK3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224802	Delta TM value showing the stabilisation of TNIK produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224767	Delta TM value showing the stabilisation of DAPK3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID436071	Percentage CHK2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1295305	Inhibition of PKA (unknown origin) using cyclic AMP response element binding protein as substrate after 5 mins in presence of [gamma-32P]-ATP	2016	Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10	A review on ROCK-II inhibitors: From molecular modelling to synthesis.
AID435669	Percentage PDK1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224751	Delta TM value showing the stabilisation of CAMK2A produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224793	Delta TM value showing the stabilisation of RSK2a produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1295304	Inhibition of human ROCK-2 using S6 peptide as substrate after 5 mins in presence of [gamma-32P]-ATP	2016	Bioorganic & medicinal chemistry letters, 05-15, Volume: 26, Issue:10	A review on ROCK-II inhibitors: From molecular modelling to synthesis.
AID1224765	Delta TM value showing the stabilisation of CK1G2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID436037	Percentage MAPKAPK3 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435427	Percentage PKBalpha activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID436076	Percentage DYRK1A activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224774	Delta TM value showing the stabilisation of p38beta produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435176	Percentage PIM2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224805	Delta TM value showing the stabilisation of VRK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224787	Delta TM value showing the stabilisation of PIM2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435339	Percentage CaMKKbeta activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224779	Delta TM value showing the stabilisation of NEK6 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224768	Delta TM value showing the stabilisation of DMPK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435713	Percentage CHK1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435728	Percentage JNK3 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435256	Percentage p38-gamma MAPK activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435847	Percentage DYRK2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435718	Percentage EF2K activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224772	Delta TM value showing the stabilisation of MAP2K6 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224750	Delta TM value showing the stabilisation of CAMK1G produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435541	Percentage PKA activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1165785	Inhibition of human recombinant ROCK-2 using KEAKEKRQEQIAKRRRLSSLRASTSKSGGSQK as substrate after 40 mins by scintillation counting analysis	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
AID1224782	Delta TM value showing the stabilisation of PAK5 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224766	Delta TM value showing the stabilisation of CK1G3 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435417	Percentage PAK4 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID325585	Binding affinity at PKA	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224797	Delta TM value showing the stabilisation of MPSK1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435501	Percentage SmMLCK activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435123	Percentage NEK7 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224783	Delta TM value showing the stabilisation of PAK6 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435638	Selectivity for ROCK1 compared to PKA	2006	The Journal of biological chemistry, Jan-06, Volume: 281, Issue:1	The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.
AID435979	Percentage MST2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1165795	Toxicity in Lewis rat at 30 mg/kg, po administered as single dose measured after 1 to 24 hrs	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
AID1224790	Delta TM value showing the stabilisation of PLK4 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224777	Delta TM value showing the stabilisation of MST4(1) produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435747	Percentage PRAK activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224778	Delta TM value showing the stabilisation of NEK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435738	Percentage p38delta MAPK activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224748	Delta TM value showing the stabilisation of AMPKA2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1165784	Inhibition of ROCK-1 (unknown origin)	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
AID1224755	Delta TM value showing the stabilisation of CAMK4 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435621	Percentage p38alpha MAPK activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID436036	Percentage Lck activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224801	Delta TM value showing the stabilisation of MST1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435454	Percentage CaMKKalpha activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID435637	Inhibitory constant against ROCK1	2006	The Journal of biological chemistry, Jan-06, Volume: 281, Issue:1	The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.
AID1224771	Delta TM value showing the stabilisation of MEK2 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435493	Percentage PKD1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID325584	Binding affinity at ROCK	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224753	Delta TM value showing the stabilisation of CAMK2D produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1165796	Reduction of peripheral lymphocyte count in Lewis rat at 30 mg/kg, po	2014	Bioorganic & medicinal chemistry letters, Oct-15, Volume: 24, Issue:20	Novel ROCK inhibitors for the treatment of pulmonary arterial hypertension.
AID435814	Percentage PIM3 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224769	Delta TM value showing the stabilisation of GSK3B produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224780	Delta TM value showing the stabilisation of OSR1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224749	Delta TM value showing the stabilisation of CAMK1D produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435987	Percentage PRK2 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224764	Delta TM value showing the stabilisation of CK1G1 produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID435238	Percentage JNK1 activity remaining in the presence of 1uM inhibitor	2007	The Biochemical journal, Dec-15, Volume: 408, Issue:3	The selectivity of protein kinase inhibitors: a further update.
AID1224770	Delta TM value showing the stabilisation of JAK1~B produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224754	Delta TM value showing the stabilisation of CAMK2G produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1224794	Delta TM value showing the stabilisation of RSK2b produced by compound binding	2007	Proceedings of the National Academy of Sciences of the United States of America, Dec-18, Volume: 104, Issue:51	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases.
AID1346986	P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346987	P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen	2019	Molecular pharmacology, 11, Volume: 96, Issue:5	A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID977608	Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB	2006	The Journal of biological chemistry, Aug-25, Volume: 281, Issue:34	Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.
AID1798514	PLK Kinase Assay from Article 10.1021/bi7008745: \\Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.\\	2007	Biochemistry, Aug-21, Volume: 46, Issue:33	Pharmacological and functional comparison of the polo-like kinase family: insight into inhibitor and substrate specificity.
AID1797134	Kinase Activity Assay from Article 10.1074/jbc.M512374200: \\Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.\\	2006	The Journal of biological chemistry, Aug-25, Volume: 281, Issue:34	Structural analysis of protein kinase A mutants with Rho-kinase inhibitor specificity.
AID1797144	Kinase Activity Assay from Article 10.1074/jbc.M508847200: \\The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.\\	2006	The Journal of biological chemistry, Jan-06, Volume: 281, Issue:1	The structure of dimeric ROCK I reveals the mechanism for ligand selectivity.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Timeframe	Studies, This Drug (%)	All Drugs %
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	5 (50.00)	29.6817
2010's	5 (50.00)	24.3611
2020's	0 (0.00)	2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Publication Type	This drug (%)	All Drugs (%)
Trials	0 (0.00%)	5.53%
Reviews	1 (10.00%)	6.00%
Case Studies	0 (0.00%)	4.05%
Observational	0 (0.00%)	0.25%
Other	9 (90.00%)	84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Substance	Relationship Strength	Studies	Classes	Roles
pd 173074 [no description available]	2.03	1	aromatic amine; biaryl; dimethoxybenzene; pyridopyrimidine; tertiary amino compound; ureas	antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; fibroblast growth factor receptor antagonist
4,5,6,7-tetrabromo-2-azabenzimidazole 4,5,6,7-tetrabromobenzotriazole: a CK2 kinase inhibitor	2.03	1
N-(2-aminoethyl)-5-chloro-1-naphthalenesulfonamide [no description available]	2.03	1	naphthalenes; sulfonic acid derivative
ag 1295 [no description available]	2.03	1	quinoxaline derivative	geroprotector
tyrphostin a23 tyrphostin A23: inhibits EGF-stimulated thymidine incorporation as well as EGF-stimulated receptor autophosphorylation & tyrosine phosphorylation & cell proliferation; structure given in first source	2.03	1	catechols
bisindolylmaleimide i bisindolylmaleimide I: a bis(indolyl)maleimide	2.03	1
bisindolylmaleimide iv [no description available]	2.03	1	indoles; maleimides
bohemine bohemine : Purine substituted on C-2, C-6 and N-9 with (3-hydroxypropyl)amino, benzylamino and isopropyl groups respectively; a synthetic, cell-permeable, cyclin-dependent kinase (CDK) inhibitor that is structurally similar to olomoucine and roscovitine.	2.03	1	purines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
chelerythrine chelerythrine : A benzophenanthridine alkaloid isolated from the root of Zanthoxylum simulans, Chelidonium majus L., and other Papaveraceae.	2.03	1	benzophenanthridine alkaloid; organic cation	antibacterial agent; antineoplastic agent; EC 2.7.11.13 (protein kinase C) inhibitor
damnacanthal damnacanthal: structure given in first source; isolated from the stem bark and roots of Morinda lucida; a selective inhibitor of p56(lck) tyrosine kinase activity	2.03	1	aldehyde; monohydroxyanthraquinone
r 59022 R 59022: diacylglycerol kinase inhibitor; structure given in first source; platelet activator factor antagonist	2.03	1	diarylmethane
n(6),n(6)-dimethyladenine N(6),N(6)-dimethyladenine : A tertiary amine that is adenine substituted at N-6 by geminal methyl groups.	2.03	1	tertiary amine
ellipticine ellipticine : A organic heterotetracyclic compound that is pyrido[4,3-b]carbazole carrying two methyl substituents at positions 5 and 11.	2.03	1	indole alkaloid; organic heterotetracyclic compound; organonitrogen heterocyclic compound; polycyclic heteroarene	antineoplastic agent; plant metabolite
go 6976 [no description available]	2.73	3	indolocarbazole; organic heterohexacyclic compound	EC 2.7.11.13 (protein kinase C) inhibitor
n-(2-(methylamino)ethyl)-5-isoquinolinesulfonamide [no description available]	2.03	1	isoquinolines; sulfonamide
ha 1004 N-(2-guanidinoethyl)-5-isoquinolinesulfonamide: structure given in first source	2.03	1	isoquinolines
fasudil fasudil: intracellular calcium antagonist; structure in first source. fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.	3.13	5	isoquinolines; N-sulfonyldiazepane	antihypertensive agent; calcium channel blocker; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; geroprotector; neuroprotective agent; nootropic agent; vasodilator agent
harmaline Harmaline: A beta-carboline alkaloid isolated from seeds of PEGANUM.. harmaline : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7 and has been reduced across the 3,4 bond.	2.03	1	harmala alkaloid	oneirogen
harmalol harmalol: inhibitor of rat liver microsomal UDP-glucuronyltransferase; RN given refers to parent cpd; structure. harmalol : A harmala alkaloid in which the harman skeleton is hydroxy-substituted at C-7 and has been reduced across the 3,4 bond.	2.03	1	harmala alkaloid	algal metabolite; EC 1.4.3.4 (monoamine oxidase) inhibitor
ic 261 [no description available]	2.03	1	indoles
indirubin-3'-monoxime indirubin-3'-monoxime: has antiangiogenic activity. indirubin-3'-monoxime : A member of the class of biindoles that is indirubin in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.03	1
nsc 664704 kenpaullone: inhibits CDK1/cyclin B; structure in first source. kenpaullone : An indolobenzazepine that is paullone in which the hydrogen at position 9 is replaced by a bromo substituent. It is an ATP-competitive inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3beta (GSK3beta).	2.44	2	indolobenzazepine; lactam; organobromine compound	cardioprotective agent; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor; geroprotector
lavendustin a lavendustin A: from Streptomyces griseolavendus; structure given in first source	2.03	1	aromatic amine
2-hydroxy-5-(2,5-dihydrobenzyl)aminobenzoic acid [no description available]	2.03	1	aromatic amine
2-(4-morpholinyl)-8-phenyl-4h-1-benzopyran-4-one 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one: specific inhibitor of phosphatidylinositol 3-kinase; structure in first source	2.73	3	chromones; morpholines; organochlorine compound	autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector
ml 9 [no description available]	2.03	1	naphthalenes; sulfonic acid derivative
nu6102 NU6102: structure in first source	2.03	1
olomoucine olomoucine: inhibits protein P34CDC2. olomoucine : A 9H-purine that is substituted by a (2-hydroxyethyl)nitrilo, benzylnitrilo and a methyl group at positions 2,6 and 9, respectively. It is a cyclin-dependent kinase inhibitor.	2.03	1	2,6-diaminopurines; ethanolamines	EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
pd 153035 4-((3-bromophenyl)amino)-6,7-dimethoxyquinazoline: structure given in first source. PD-153035 : A member of the class of quinazolines carrying a 3-bromophenylamino substituent at position 4 and two methoxy substituents at positions 6 and 7.	2.03	1	aromatic amine; aromatic ether; bromobenzenes; quinazolines; secondary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; epidermal growth factor receptor antagonist
pd 169316 2-(4-nitrophenyl)-4-(4-fluorophenyl)-5-(4-pyridinyl)-1H-imidazole: p38 MAP kinase inhibitor	2.03	1	imidazoles
pd 98059 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one: inhibits MAP kinase kinase (MEK) activity, p42 MAPK and p44 MAPK; structure in first source. 2-(2-amino-3-methoxyphenyl)chromen-4-one : A member of the class of monomethoxyflavones that is 3'-methoxyflavone bearing an additional amino substituent at position 2'.	2.03	1	aromatic amine; monomethoxyflavone	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector
1-NA-PP1 [no description available]	2.44	2	pyrazolopyrimidine	tyrosine kinase inhibitor
ag 1879 3-(4-chlorophenyl)-1-(1,1-dimethylethyl)-1H-pyrazolo(3,4-d)pyrimidin-4-amine: Fyn kinase inhibitor	2.44	2	aromatic amine; monochlorobenzenes; pyrazolopyrimidine	beta-adrenergic antagonist; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector
ro 31-8220 Ro 31-8220: a protein kinase C inhibitor	2.03	1	imidothiocarbamic ester; indoles; maleimides	EC 2.7.11.13 (protein kinase C) inhibitor
sb 220025 SB 220025: inhibits p38 mitogen-activated protein kinase; structure in first source. SB220025 : Am member of the class of imidazoles carrying piperidin-4-yl, 4-fluophenyl and 2-aminopyrimidin-4-yl substituents at posiitons 1, 4 and 5 respectively.	2.03	1	aminopyrimidine; imidazoles; organofluorine compound; piperidines	angiogenesis inhibitor; anti-inflammatory agent; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
sb 239063 SB 239063: structure in first source. SB-239063 : A member of the class of imidazoles carrying 4-hydroxycyclohexyl, 4-fluorophenyl and 2-methoxypyrimidin-4-yl substituents at positions 1, 4 and 5 respectively.	2.03	1	imidazoles
sb 202190 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole: structure given in first source; inhibits p38 MAP kinase	2.44	2	imidazoles; organofluorine compound; phenols; pyridines	apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor
imatinib [no description available]	2.03	1	aromatic amine; benzamides; N-methylpiperazine; pyridines; pyrimidines	antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
whi p180 [no description available]	2.03	1
zm 336372 N-(5-(3-dimethylaminobenzamido)-2-methylphenyl)-4-hydroxybenzamide: an inhibitor of c-Raf; activates Raf-1; structure in first source	2.44	2	benzamides
dichlororibofuranosylbenzimidazole Dichlororibofuranosylbenzimidazole: An RNA polymerase II transcriptional inhibitor. This compound terminates transcription prematurely by selective inhibition of RNA synthesis. It is used in research to study underlying mechanisms of cellular regulation.	2.03	1
pyrazolanthrone pyrazolanthrone: JNK (c-Jun N-terminal kinase) inhibitor; structure in first source. anthra[1,9-cd]pyrazol-6(2H)-one : A member of the class of anthrapyrazoles that is anthra[1,9-cd]pyrazole substituted at position 6 by an oxo group. An inhibitor of c-Jun N-terminal kinase.	2.44	2	anthrapyrazole; aromatic ketone; cyclic ketone	antineoplastic agent; c-Jun N-terminal kinase inhibitor; geroprotector
1,4-naphthoquinone naphthoquinone : A polycyclic aromatic ketone metabolite of naphthalene.. 1,4-naphthoquinone : The parent structure of the family of 1,4-naphthoquinones, in which the oxo groups of the quinone moiety are at positions 1 and 4 of the naphthalene ring. Derivatives have pharmacological properties.	2.03	1	1,4-naphthoquinones
staurosporine [no description available]	2.96	4	indolocarbazole alkaloid; organic heterooctacyclic compound	apoptosis inducer; bacterial metabolite; EC 2.7.11.13 (protein kinase C) inhibitor; geroprotector
arctigenin arctigenin: precursor to catechols; in many plants	2.03	1	lignan
chelerythrine chloride [no description available]	2.03	1
fascaplysine fascaplysine: from tropic sea sponges	2.03	1
5-iodotubercidin 7-iodotubercidin: inhibits Toxoplasma gondii adenosine kinase	2.03	1	organoiodine compound
imatinib mesylate imatinib methanesulfonate : A methanesulfonate (mesylate) salt that is the monomesylate salt of imatinib. Used for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours.	2.03	1	methanesulfonate salt	anticoronaviral agent; antineoplastic agent; apoptosis inducer; tyrosine kinase inhibitor
gefitinib [no description available]	2.03	1	aromatic ether; monochlorobenzenes; monofluorobenzenes; morpholines; quinazolines; secondary amino compound; tertiary amino compound	antineoplastic agent; epidermal growth factor receptor antagonist
cki 7 N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide: casein kinase I inhibitor; structure given in first source. N-(2-aminoethyl)-5-chloroisoquinoline-8-sulfonamide : A member of the class of isoquinolines that is isoquinoline-8-sulfonamide which is substituted by chlorine at position 5 and in which the sulfonamide nitrogen is substituted by a 2-aminoethyl group. It is an inhibitor of casein kinase I.	2.03	1	isoquinolines; organochlorine compound; primary amino compound; sulfonamide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
vatalanib [no description available]	2.03	1	monochlorobenzenes; phthalazines; pyridines; secondary amino compound	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; vascular endothelial growth factor receptor antagonist
ruboxistaurin ruboxistaurin: inhibits protein kinase C beta; structure in first source	2.44	2
birb 796 [no description available]	2.03	1	aromatic ether; morpholines; naphthalenes; pyrazoles; ureas	EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; immunomodulator
cyc 202 seliciclib : 2,6-Diaminopurine carrying benzylamino, (2R)-1-hydroxybutan-2-yl and isopropyl substituents at C-6, C-2-N and N-9 respectively. It is an experimental drug candidate in the family of pharmacological cyclin-dependent kinase (CDK) inhibitors.	2.44	2	2,6-diaminopurines	antiviral drug; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor
sb 203580 [no description available]	2.44	2	imidazoles; monofluorobenzenes; pyridines; sulfoxide	EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; geroprotector; Hsp90 inhibitor; neuroprotective agent
sb 216763 [no description available]	2.03	1	indoles; maleimides
erlotinib [no description available]	2.03	1	aromatic ether; quinazolines; secondary amino compound; terminal acetylenic compound	antineoplastic agent; epidermal growth factor receptor antagonist; protein kinase inhibitor
sorafenib [no description available]	2.44	2	(trifluoromethyl)benzenes; aromatic ether; monochlorobenzenes; phenylureas; pyridinecarboxamide	angiogenesis inhibitor; anticoronaviral agent; antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; ferroptosis inducer; tyrosine kinase inhibitor
wortmannin [no description available]	2.44	2	acetate ester; cyclic ketone; delta-lactone; organic heteropentacyclic compound	anticoronaviral agent; antineoplastic agent; autophagy inhibitor; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; geroprotector; Penicillium metabolite; radiosensitizing agent
5-iodoindirubin-3'-monoxime 5-iodoindirubin-3'-monoxime: inhibits GSK-3beta	2.03	1
2H-pyrazolo[4,3-b]quinoxalin-3-amine [no description available]	2.03	1	quinoxaline derivative
n-(4-methoxybenzyl)-n'-(5-nitro-1,3-thiazol-2-yl)urea N-(4-methoxybenzyl)-N'-(5-nitro-1,3-thiazol-2-yl)urea: structure in first source	2.44	2
y 27632 Y 27632: RN given for di-HCl salt; inhibits Rho-associated protein kinase; inhibits calcium sensitization to affect smooth muscle relaxation; structure in first source. Y-27632 : A monocarboxylic acid amide that is trans-[(1R)-1-aminoethyl]cyclohexanecarboxamide in which one of the nitrogens of the aminocarbony group is substituted by a pyridine nucleus. It has been shown to exhibit inhibitory activity against Rho-associated protein kinase (ROCK) enzyme.	3.29	6	aromatic amide
7-n-butyl-6-(4'-hydroxyphenyl)-5h-pyrrolo(2,3b)pyrazine [no description available]	2.03	1
6-bromoindirubin-3'-oxime 6-bromoindirubin-3'-oxime: structure in first source. 6-bromoindirubin-3'-oxime : A member of the class of biindoles that is indirubin substituted at position 6 by a bromo group and in which the keto group at position 3' has undergone condensation with hydroxylamine to form the corresponding oxime.	2.03	1
h 89 N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide: structure given in first source. N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A member of the class of isoquinolines that is the sulfonamide obtained by formal condensation of the sulfo group of isoquinoline-5-sulfonic acid with the primary amino group of N(1)-[3-(4-bromophenyl)prop-2-en-1-yl]ethane-1,2-diamine. It is a protein kinase A inhibitor.. (E)-N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide : A N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide in which the double bond adopts a trans-configuration.	2.44	2	N-[2-(4-bromocinnamylamino)ethyl]isoquinoline-5-sulfonamide
kt 5720 KT 5720: indolocarbazole; synthetic derivative of K 252a. KT 5720 : An organic heterooctacyclic compound that is 1H,1'H-2,2'-biindole in which the nitrogens have undergone formal oxidative coupling to positions 2 and 5 of hexyl (3S)-3-hydroxy-2-methyltetrahydrofuran-3-carboxylate (the 2R,3S,5S product), and in which the 3 and 3' positions of the biindole moiety have also undergone formal oxidative coupling to positions 3 and 4 of 1,5-dihydro-2H-pyrrol-2-one.	2.03	1	carboxylic ester; gamma-lactam; hemiaminal; indolocarbazole; organic heterooctacyclic compound; semisynthetic derivative; tertiary alcohol	EC 2.7.11.11 (cAMP-dependent protein kinase) inhibitor
purvalanol a 6-((3-chloro)anilino)-2-(isopropyl-2-hydroxyethylamino)-9-isopropylpurine: purvalanol A is the (1R)-isomer;	2.44	2	purvalanol
2-methyl-5-(4-methylanilino)-1,3-benzothiazole-4,7-dione [no description available]	2.03	1	aminotoluene
r 59949 R 59949: diacylglycerol kinase inhibitor	2.03	1	diarylmethane
3,3',4,5'-tetrahydroxystilbene 3,3',4,5'-tetrahydroxystilbene: demethyl derivative of isorhapontigenin; structure in first source; a Syk kinase inhibitor; found in heartwood of FABACEAE; inhibitor of photosynthesis in spinach chloroplasts; may be inhibitor of plant growth; RN given refers to (E)-isomer. piceatannol : A stilbenol that is trans-stilbene in which one of the phenyl groups is substituted by hydroxy groups at positions 3 and 4, while the other phenyl group is substituted by hydroxy groups at positions 3 and 5.	2.03	1	catechols; polyphenol; resorcinols; stilbenol	antineoplastic agent; apoptosis inducer; geroprotector; hypoglycemic agent; plant metabolite; protein kinase inhibitor; tyrosine kinase inhibitor
Src Inhibitor-1 Src Inhibitor-1 : A member of the class of quinazolines that is quinazoline which is substituted at position 4 by a p-phenoxyanilino group and at positions 6 and 7 by methoxy groups. It is a potent, competitive dual site (both the ATP- and peptide-binding) Src kinase inhibitor. Src Inhibitor-1 is one of the 'gold standards' for Src kinase inhibition that has been shown to use PP1 or PP2 in parallel with Src-I1 to inhbit Src family kinases.	2.03	1	aromatic ether; polyether; quinazolines; secondary amino compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
tg 003 TG 003: a Clk inhibitor; structure in first source	2.03	1
thiourea Thiourea: A photographic fixative used also in the manufacture of resins. According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), this substance may reasonably be anticipated to be a carcinogen (Merck Index, 9th ed). Many of its derivatives are ANTITHYROID AGENTS and/or FREE RADICAL SCAVENGERS.. thiourea : The simplest member of the thiourea class, consisting of urea with the oxygen atom substituted by sulfur.	2.03	1	one-carbon compound; thioureas; ureas	antioxidant; chromophore
sc 514 SC 514: inhibits IkappaB kinase-2; structure in first source	2.03	1	ring assembly; thiophenes
u 0126 U 0126: protein kinase kinase inhibitor; structure in first source	2.44	2	aryl sulfide; dinitrile; enamine; substituted aniline	antineoplastic agent; antioxidant; apoptosis inducer; EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor; osteogenesis regulator; vasoconstrictor agent
dasatinib N-(2-chloro-6-methylphenyl)-2-((6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-yl)amino)-1,3-thiazole-5-carboxamide: a dasatinib prodrug; structure in first source. dasatinib (anhydrous) : An aminopyrimidine that is 2-methylpyrimidine which is substituted at position 4 by the primary amino group of 2-amino-1,3-thiazole-5-carboxylic acid and at position 6 by a 4-(2-hydroxyethyl)piperazin-1-yl group, and in which the carboxylic acid group has been formally condensed with 2-chloro-6-methylaniline to afford the corresponding amide. A multi-targeted kinase inhibitor, it is used, particularly as the monohydrate, for the treatment of chronic, accelerated, or myeloid or lymphoid blast phase chronic myeloid leukemia. Note that the name 'dasatinib' is used to refer to the monohydrate (USAN) as well as to anhydrous dasatinib (INN).	2.03	1	1,3-thiazoles; aminopyrimidine; monocarboxylic acid amide; N-(2-hydroxyethyl)piperazine; N-arylpiperazine; organochlorine compound; secondary amino compound; tertiary amino compound	anticoronaviral agent; antineoplastic agent; tyrosine kinase inhibitor
ha 1100 HA 1100: intracellular calcium antagonist	2.44	2
7-epi-hydroxystaurosporine [no description available]	2.03	1
gtp 14564 [no description available]	2.03	1	pyrazoles; ring assembly
sb 218078 [no description available]	2.03	1	indolocarbazole
sb 415286 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione: a glycogen synthase kinase-3 inhibitor; structure in first source	2.03	1	C-nitro compound; maleimides; monochlorobenzenes; phenols; secondary amino compound; substituted aniline	antioxidant; apoptosis inducer; EC 2.7.11.26 (tau-protein kinase) inhibitor; neuroprotective agent
alsterpaullone alsterpaullone: structure in first source. alsterpaullone : An organic heterotetracyclic compound that is 1,3-dihydro-2H-1-benzazepin-2-one which shares its 4-5 bond with the 3-2 bond of 5-nitro-1H-indole.	2.44	2	C-nitro compound; caprolactams; organic heterotetracyclic compound	anti-HIV-1 agent; antineoplastic agent; apoptosis inducer; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor; EC 2.7.11.22 (cyclin-dependent kinase) inhibitor; EC 2.7.11.26 (tau-protein kinase) inhibitor
1-tert-butyl-3-naphthalen-1-ylmethyl-1h-pyrazolo(3,4-d)pyrimidin-4-ylemine [no description available]	2.03	1	pyrazolopyrimidine	tyrosine kinase inhibitor
quercetin [no description available]	2.03	1	7-hydroxyflavonol; pentahydroxyflavone	antibacterial agent; antineoplastic agent; antioxidant; Aurora kinase inhibitor; chelator; EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor; geroprotector; phytoestrogen; plant metabolite; protein kinase inhibitor; radical scavenger
apigenin Chamomile: Common name for several daisy-like plants (MATRICARIA; TRIPLEUROSPERMUM; ANTHEMIS; CHAMAEMELUM) native to Europe and Western Asia, now naturalized in the United States and Australia.	2.03	1	trihydroxyflavone	antineoplastic agent; metabolite
daphnetin [no description available]	2.03	1	hydroxycoumarin
harmine Harmine: Alkaloid isolated from seeds of PEGANUM HARMALA; ZYGOPHYLLACEAE. It is identical to banisterine, or telepathine, from Banisteria caapi and is one of the active ingredients of hallucinogenic drinks made in the western Amazon region from related plants. It has no therapeutic use, but (as banisterine) was hailed as a cure for postencephalitic PARKINSON DISEASE in the 1920's.. harmine : A harmala alkaloid in which the harman skeleton is methoxy-substituted at C-7.	2.03	1	harmala alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; metabolite
genistein [no description available]	2.03	1	7-hydroxyisoflavones	antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor
harman harman: a beta-carboline; RN given refers to parent cpd; structure. harman : An indole alkaloid fundamental parent with a structure of 9H-beta-carboline carrying a methyl substituent at C-1. It has been isolated from the bark of Sickingia rubra, Symplocus racemosa, Passiflora incarnata, Peganum harmala, Banisteriopsis caapi and Tribulus terrestris, as well as from tobacco smoke. It is a specific, reversible inhibitor of monoamine oxidase A.	2.03	1	harmala alkaloid; indole alkaloid fundamental parent; indole alkaloid	anti-HIV agent; EC 1.4.3.4 (monoamine oxidase) inhibitor; plant metabolite
wedelolactone wedelolactone: antihepatotoxic coumestan from Eclipta prostrata and Wedelia calendulacea (both Asteraceae); structure given in first source. wedelolactone : A member of the class of coumestans that is coumestan with hydroxy substituents as positions 1, 8 and 9 and a methoxy substituent at position 3.	2.03	1	aromatic ether; coumestans; delta-lactone; polyphenol	antineoplastic agent; apoptosis inducer; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; hepatoprotective agent; metabolite
rottlerin rottlerin: an angiogenesis inhibitor; an inhibitor of protein kinase Cdelta (PKCdelta) and calmodulin kinase III; RN refers to (E)-isomer; do not confuse this chalcone with an anthraquinone that is also called rottlerin (RN 481-72-1);. rottlerin : A chromenol that is 2,2-dimethyl-2H-chromene substituted by hydroxy groups at positions 5 and 7, a 3-acetyl-2,4,6-trihydroxy-5-methylbenzyl group at position 6 and a (1E)-3-oxo-1-phenylprop-1-en-3-yl group at position 8. A potassium channel opener, it is isolated from Mallotus philippensis.	2.03	1	aromatic ketone; benzenetriol; chromenol; enone; methyl ketone	anti-allergic agent; antihypertensive agent; antineoplastic agent; apoptosis inducer; K-ATP channel agonist; metabolite
sirolimus Sirolimus: A macrolide compound obtained from Streptomyces hygroscopicus that acts by selectively blocking the transcriptional activation of cytokines thereby inhibiting cytokine production. It is bioactive only when bound to IMMUNOPHILINS. Sirolimus is a potent immunosuppressant and possesses both antifungal and antineoplastic properties.. sirolimus : A macrolide lactam isolated from Streptomyces hygroscopicus consisting of a 29-membered ring containing 4 trans double bonds, three of which are conjugated. It is an antibiotic, immunosupressive and antineoplastic agent.	2.03	1	antibiotic antifungal drug; cyclic acetal; cyclic ketone; ether; macrolide lactam; organic heterotricyclic compound; secondary alcohol	antibacterial drug; anticoronaviral agent; antineoplastic agent; bacterial metabolite; geroprotector; immunosuppressive agent; mTOR inhibitor
geldanamycin [no description available]	2.03	1	1,4-benzoquinones; ansamycin; carbamate ester; organic heterobicyclic compound	antimicrobial agent; antineoplastic agent; antiviral agent; cysteine protease inhibitor; Hsp90 inhibitor
su 9516 [no description available]	2.03	1
kn 93 KN 93: reduces dopamine content in PC12h cells. KN-93 : A sulfonamide resulting from the formal condensation of p-methoxybenzenesulfonic acid with the anilino nitrogen of 2-(aminomethyl)-N-(2-hydroxyethyl)aniline in which the hydrogens of the primary amino group have been replaced by methyl and p-chlorocinnamyl groups. KN-93 is a selective inhibitor of Ca(2+)/calmodulin-dependent protein kinase II.	2.03	1	monochlorobenzenes; monomethoxybenzene; primary alcohol; sulfonamide; tertiary amino compound	EC 2.7.11.17 (Ca(2+)/calmodulin-dependent protein kinase) inhibitor; geroprotector
su 6656 SU 6656: a c-Src kinase inhibitor; used to probe growth signaling; structure in first source. SU6656 : A member of the class of oxindoles that is 3-methyleneoxindole in which the hydrogeh at position 5 has been replaced by a dimethylaminosulfonyl group and in which one of the hydrogens of the methylene group has been replaced by a 4,5,6,7-tetrahydro-indol-2-yl group. It is a specific inhibitor of Src family kinase.	2.44	2
tyrphostin ag-494 AG 494: tyrphostin that blocks Cdk2 activation; structure in first source	2.03	1
ag-490 [no description available]	2.03	1	catechols; enamide; monocarboxylic acid amide; nitrile; secondary carboxamide	anti-inflammatory agent; antioxidant; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; geroprotector; STAT3 inhibitor
orantinib orantinib: an antiangiogenic agent. orantinib : An oxindole that is 3-methyleneoxindole in which one of the hydrogens of the methylene group is substituted by a 2-(2-carboxyethyl)-3,5-dimethylpyrrol-3-yl group. It is an ATP-competitive inhibitor of the tyrosine kinase activity of fibroblast growth factor receptor 1.	2.03	1
su 11248 [no description available]	2.74	3	monocarboxylic acid amide; pyrroles	angiogenesis inhibitor; antineoplastic agent; EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; immunomodulator; neuroprotective agent; vascular endothelial growth factor receptor antagonist
su 11652 SU 11652: a tyrosine kinase inhibitor; amino acid sequence in first source. SU11652 : A member of the class of pyrrolecarboxamides obtained by formal condensation of the carboxy group of 5-[(Z)-(5-chloro-2-oxo-1,2-dihydroindol-3-ylidene)methyl]-2,4-dimethylpyrrole-3-carboxylic acid with the primary amino group of N(1),N(1)-diethylethane-1,2-diamine.	2.03	1	olefinic compound; organochlorine compound; oxindoles; pyrrolecarboxamide; tertiary amino compound	EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor; EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor
2-tert-butyl-9-fluoro-3,6-dihydro-7h-benz(h)imidazo(4,5-f)isoquinoline-7-one 2-tert-butyl-9-fluoro-3,6-dihydro-7H-benz(h)imidazo(4,5-f)isoquinoline-7-one: a janus-activated kinase inhibitor. 2-tert-butyl-9-fluoro-1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one : An organic heterotetracyclic compound that is 1,6-dihydrobenzo[h]imidazo[4,5-f]isoquinolin-7-one bearing additional tert-butyl and fluoro substituents at positions 2 and 9 respectively.	2.03	1	organic heterotetracyclic compound; organofluorine compound	EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor
vx680 [no description available]	2.44	2	N-arylpiperazine
st 638 [no description available]	2.03	1
su 1498 SU 1498: structure in first source. SU1498 : A monocarboxylic acid amide obtained by formal condensation of the carboxy group of (2E)-2-cyano-3-[4-hydroxy-3,5-di(propan-2-yl)phenyl]prop-2-enoic acid with the amino group of 3-phenylpropylamine.	2.03	1	enamide; monocarboxylic acid amide; nitrile; phenols; secondary carboxamide	vascular endothelial growth factor receptor antagonist
monorden monorden: inhibits HSP90 Heat-Shock Proteins, DNA topoisomerase VI and human Topoisomerase II	2.03	1	cyclic ketone; enone; epoxide; macrolide antibiotic; monochlorobenzenes; phenols	antifungal agent; metabolite; tyrosine kinase inhibitor
ml 3403 [no description available]	2.03	1
d 4476 [no description available]	2.44	2	imidazoles
GSK3-XIII GSK3-XIII : A member of the class of aromatic amines that is ammonia with two of the hydrogens replaced by 5-methylpyrazol-3-yl and 2-phenylquinazolin-4-yl groups.	2.03	1	aromatic amine; pyrazoles; quinazolines; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
axitinib [no description available]	2.03	1	aryl sulfide; benzamides; indazoles; pyridines	antineoplastic agent; tyrosine kinase inhibitor; vascular endothelial growth factor receptor antagonist
2-[(3-iodophenyl)methylthio]-5-pyridin-4-yl-1,3,4-oxadiazole [no description available]	2.03	1	aryl sulfide
gdp 366 GDP 366: an antineoplastic agent; structure in first source	2.03	1
aminopurvalanol a aminopurvalanol A: casein kinase I alpha inhibitor; structure in first source	2.03	1	monochlorobenzenes; purvalanol	protein kinase inhibitor
cvt 313 CVT 313: a potent inhibitor of CDK2 that prevents neointimal proliferation; structure given in first source	2.03	1
pd 184352 2-(2-chloro-4-iodophenylamino)-N-cyclopropylmethoxy-3,4-difluorobenzamide: inhibits MAP kinase kinase; structure in first source	2.03	1	aminobenzoic acid
bibx 1382bs BIBX 1382BS: an ErbB receptor kinase inhibitor; no further information available 4/2001	2.03	1	substituted aniline
sl 327 SL 327: a MEK inhibitor. SL-327 : A nitrile that is acrylonitrile in which the hydrogen attached to the same carbon as the cyano group has been replaced by an o-(trifluoromethyl)phenyl group, while the remaining hydrogens of the ethenyl group have been replaced by amino and (4-aminophenyl)sulfanyl groups. The configuration of the double bond is not specified. It is an inhibitor of MEK1 and MEK2.	2.03	1
tws 119 [no description available]	2.03	1	pyrroles
krn 633 N-(2-chloro-4-((6,7-dimethoxy-4-quinazolinyl)oxy)phenyl)-N'-propylurea: a VEGF receptor-2 tyrosine kinase inhibitor; structure in first source	2.03	1
((3z)-n-(3-chlorophenyl)-3-((3,5-dimethyl-4-((4-methylpiperazin-1-yl)carbonyl)-1h-pyrrol-2-yl)methylene)-n-methyl-2-oxo-2,3-dihydro-1h-indole-5-sulfonamide) [no description available]	2.03	1	sulfonamide
c 1368 [no description available]	2.03	1
pq 401 PQ 401: an IGF receptor type I antagonist; structure in first source	2.03	1	quinolines
jnj 10198409 [no description available]	2.03	1
cp 547632 3-(4-bromo-2,6-difluorobenzyloxy)-5-(3-(4-pyrrolidin-1-ylbutyl)ureido)isothiazole-4-carboxylic acid amide: inhibits vascular endothelial growth factor receptor-2 tyrosine kinase; structure in first source	2.03	1
bms345541 4(2'-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline: structure in first source	2.03	1	quinoxaline derivative
gw843682x [no description available]	2.03	1	(trifluoromethyl)benzenes
pd 0325901 mirdametinib: has antineoplastic activity; appears to be a MEK inhibitor. PD 0325901 : A hydroxamic acid ester that is benzhydroxamic acid (N-hydroxybenzamide) in which the hydroxamic acid group has been converted to the corresponding 2,3-dihydroxypropyl ester and in which the benzene ring has been substituted at position 2 by a (2-fluoro-4-iodophenyl)amino group and at positions 3 and 4 by fluorines (the R enantiomer).	2.03	1	difluorobenzene; hydroxamic acid ester; monofluorobenzenes; organoiodine compound; propane-1,2-diols; secondary amino compound	antineoplastic agent; EC 2.7.12.2 (mitogen-activated protein kinase kinase) inhibitor
nu 7026 2-(morpholin-4-yl)benzo(h)chromen-4-one: a radiosensitizing agent that inhibits DNA-dependent protein kinase; structure in first source	2.03	1	organic heterotricyclic compound; organooxygen compound
pi103 PI103: pyridofuropyrimidine antineoplastic; a potent inhibitor of class I phosphatidylinositide 3-kinases (PI3K); structure in first soruce	2.44	2	aromatic amine; morpholines; organic heterotricyclic compound; phenols; tertiary amino compound	antineoplastic agent; EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor; mTOR inhibitor
y 27632, dihydrochloride, (4(r)-trans)-isomer [no description available]	2.03	1
ps1145 PS1145: IkappaB kinase inhibitor; structure in first source	2.03	1	beta-carbolines
chir 99021 Chir 99021: structure in first source. CHIR 99021 : A member of the class of aminopyrimidines that is 2-aminopyrimidine substituted at positions N2, 5 and 6 by (5-cyanopyridin-2-yl)ethyl, 4-methylimidazol-2-yl and 2,4-dichlorophenyl groups respectively.	2.03	1	aminopyridine; aminopyrimidine; cyanopyridine; diamine; dichlorobenzene; imidazoles; secondary amino compound	EC 2.7.11.26 (tau-protein kinase) inhibitor
bx795 BX795: structure in first source	2.03	1	ureas
a 443654 A 443654: an Akt kinase inhibitor; structure in first source	2.03	1	indoles
sl0101 SL0101: p90 Ribosomal S6 Kinase; structure in first source	2.03	1
bi 2536 [no description available]	2.03	1
fr 180204 FR 180204: structure in first source	2.03	1	pyrazoles; ring assembly
dorsomorphin dorsomorphin: an AMPK inhibitor. dorsomorphin : A pyrazolopyrimidine that is pyrazolo[1,5-a]pyrimidine which is substituted at positions 3 and 6 by pyridin-4-yl and p-[2-(piperidin-1-yl)ethoxy]phenyl groups, respectively. It is a potent, selective, reversible, and ATP-competitive inhibitor of AMPK (AMP-activated protein kinase, EC 2.7.11.31) and a selective inhibitor of bone morphogenetic protein (BMP) signaling.	2.03	1	aromatic ether; piperidines; pyrazolopyrimidine; pyridines	bone morphogenetic protein receptor antagonist; EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor
gw 2580 5-(3-methoxy-4-((4-methoxybenzyl)oxy)benzyl)pyrimidine-2,4-diamine: a cFMS kinase inhibitor; structure in first source	2.03	1
cgp 57380 CGP 57380: inhibits the mitogen-activated protein kinase-interacting kinase Mnk1	2.03	1	pyrazolopyrimidine
sb 772077-b [no description available]	2.1	1
bi d1870 [no description available]	2.03	1
lrrk2-in1 LRRK2-IN1: inhibits leucine-rich repeat kinase 2; structure in first source	2.08	1	aromatic amine; aromatic ether; N-acylpiperidine; N-alkylpiperazine; pyrimidobenzodiazepine; secondary amino compound; tertiary amino compound	antineoplastic agent; EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor
lfm a13 LFM-A13 : An enamide obtained by formal condensation of the carboxy group of (2Z)-2-cyano-3-hydroxybut-2-enoic acid with the amino group of 2,5-dibromoaniline. It is a dual-function inhibitor of Bruton's tyrosine kinase (BTK) and Polo-like kinases (PLK) that exhibits anticancer properties.	2.03	1	aromatic amide; dibromobenzene; enamide; enol; nitrile; secondary carboxamide	antineoplastic agent; apoptosis inducer; EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor; EC 2.7.11.21 (polo kinase) inhibitor; geroprotector; platelet aggregation inhibitor
akt-i-1,2 compound Akt-I-1,2 compound: an aminopeptidase P inhibitor; structure in first source	2.03	1
chir 258 [no description available]	2.03	1
hymenialdisine [no description available]	2.03	1
isogranulatimide isogranulatimide: G2 checkpoint inhibitor; structure in first source	2.03	1
debromohymenialdisine [no description available]	2.03	1

Condition	Relationship Strength	Studies
Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.	2.1	1
Pulmonary Hypertension [description not available]	2.1	1
Hypertension, Pulmonary Increased VASCULAR RESISTANCE in the PULMONARY CIRCULATION, usually secondary to HEART DISEASES or LUNG DISEASES.	2.1	1

h 1152

Description

Cross-References

Synonyms (34)

Research Excerpts

Bioavailability

Roles (1)

Drug Classes (2)

Protein Targets (21)

Inhibition Measurements

Biological Processes (292)

Molecular Functions (50)

Ceullar Components (86)

Bioassays (152)

Research

Studies (10)

Market Indicators

Research Demand Index: 21.32

Study Types

h 1152

Description

Cross-References

Synonyms (34)

Research Excerpts

Bioavailability

Roles (1)

Drug Classes (2)

Protein Targets (21)

Inhibition Measurements

Biological Processes (292)

Molecular Functions (50)

Ceullar Components (86)

Bioassays (152)

Research

Studies (10)

Market Indicators

Research Demand Index: 21.32

Study Types

Related Drugs (151)

Related Conditions (3)